Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

Cystic Fibrosis Clinical Trial

— CF-AOX  

Official title:

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02690064
• Other study ID #: CF-AOX
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 2015
• Est. completion date: January 2025

Study information

• Verified date: January 2024
• Source: Augusta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.

Description:

Cystic Fibrosis (CF) is the most common fatal genetic disease in North America. The most disturbing aspect of CF is the associated premature death, most often due to respiratory complications. Clinical manifestations of CF include not only lung dysfunction, but many other systemic consequences as well. Systemic oxidative stress and exercise intolerance are established phenotypes in patients with CF. Additionally, for the first time the investigators have recently published the presence of systemic endothelial dysfunction in a cohort of young patients with CF who exhibited normal oxygen saturation and spirometric function.

Exercise intolerance, the limitation of the ability to perform exercise at the expected level, has been shown to predict mortality in patients with CF independent of lung function. Exercise capacity (VO2 peak), an objective measurement of exercise tolerance, drops approximately 5-8% per year in patients with CF. This excessive decay in exercise capacity not only leads to more pulmonary infections and deterioration of lung function, it represents a 5-8 fold decline compared to healthy sedentary adults. Preventing the excessive annual reduction in exercise capacity is essential to increasing the quality of life and longevity of patients with CF. However, a critical barrier to improving exercise capacity in CF is the investigators lack of knowledge regarding the different physiological mechanisms that contribute to exercise intolerance. It is important to emphasize that decreases in lung function (FEV1) do not always contribute to reductions in VO2 peak. Furthermore, less than 2% of patients who have an FEV1 greater than 50% predicted will have a significant drop in hemoglobin oxygen saturation (SpO2) during maximal exercise. These data suggest that mechanisms other than lung function induced hypoxemia may be contributing to exercise intolerance in patients with CF.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 13
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 7 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of CF and healthy controls

• Men and women (> 18 yrs. old)

• Boys and girls (7-17 yrs. old)

• FEV1 percent predicted > 30%

• Patients with or without CF related diabetes

• Resting oxygen saturation (room air) >90%

• Traditional CF-treatment medications

• Ability to perform reliable/reproducible PFTs

• Clinically stable for 2 weeks (no exacerbations or need for antibiotic treatment within 2 weeks of testing or major change in medical status)

• Pancreatic sufficient and pancreatic insufficient patients

Exclusion Criteria:

• Children 6 yrs. old and younger

• FEV1 percent predicted < 30%

• Resting oxygen saturation (room air) < 90%

• Clinical diagnosis of heart disease, PAH

• Febrile illness within two weeks of visit

• Currently smoking, pregnant, or nursing

• Individuals on vaso-active medications (i.e. nitrates, beta blockers, ACE inhibitors, etc.)

• Patients with B. cepacia (only ~3% of our CF center patient population)

• Treatment for pulmonary exacerbation within 4 weeks of a study visit

Related Conditions & MeSH terms

• Cystic Fibrosis

Intervention

Dietary Supplement:
• Acute Antioxidant
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
• Chronic Antioxidant
Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.

Other:
• Placebo
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Locations

Country	Name	City	State
United States	Georgia Prevention Institute	Augusta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Augusta University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute Change in Flow mediated dilation	Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment	Change from baseline (2 hours)
Primary	Chronic Change in Flow mediated dilation	Flow-Mediated Dilation will be determined at baseline, week 4, week 8 and week 12.	Baseline, week 4, week 8, and week 12
Primary	Acute Change in exercise capacity (VO2 peak)	Subjects will perform a baseline maximal exercise capacity test and on a separate visit perform a maximal exercise capacity test 2 hours following acute antioxidant treatment	Baseline and 2 hours following acute antioxidant treatment
Primary	Chronic Change in exercise capacity (VO2 peak)	Subjects will perform a maximal exercise capacity test at baseline, week 4, week 8, and week 12.	Baseline, week 4, week 8, and week 12